Medical Frontline Drug News
On July 22, Ausper Biopharma Co., Ltd. and AusperBio Therapeutics Inc. announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration had approved the initiation of a Phase 3 clinical trial for their core candidate drug, AHB-137. AHB-137 is a non-conjugated antisense oligonucleotide (ASO) drug with the potential to become a cornerstone for the clinical cure of chronic hepatitis B.On July 22, the CDE website announced that Telix Pharmaceuticals' Class 1 new drug, 177Lu-HuJ591 antibody injection, has been approved for clinical trials. It is intended to be developed for treating patients with metastatic castration-resistant prostate cancer (mCRPC) who are positive for prostate-specific membrane antigen (PSMA) and have progressed after previous treatment with androgen receptor pathway inhibitors (ARPI).July 22, YingBio announces that the U.S. FDA has granted Fast Track designation to the next-generation HER3 antibody-drug conjugate (ADC) DB-1310Indication: For the treatment of adult patients with advanced/unresectable or metastatic non-squamous non-small cell lung cancer (nsqNSCLC) who have disease progression during or after treatment with a third-generation EGFR tyrosine kinase inhibitor and platinum-based chemotherapy, and who harbor EGFR exon 19 deletions or L858R mutations.On July 23, SIBP-A16 Injection, a Class I new drug developed by Shanghai Institute of Biological Products, China National Pharmaceutical Group (Sinopharm), received the clinical trial approval notice from the National Medical Products Administration (NMPA) and is intended to be used for the prevention of lower respiratory tract infections caused by Respiratory Syncytial Virus (RSV).Investment and Financing in the Pharmaceutical Industry
On July 22, Novatim announced a strategic partnership with U.S.-based biopharmaceutical company ERIGEN LLC. Both parties signed an exclusive overseas licensing agreement for KQ-2003, Novatim's globally first-in-class dual-targeting CAR-T cell therapy product with enhanced parallel targeting. This collaboration covers global rights outside Greater China (excluding India, Turkey, and Russia), granting ERIGEN exclusive development, registration, and commercialization rights for the product in the relevant regions.Technology-Driven Drug ResearchRecently, Aaron T. Whiteley from the University of Colorado Boulder in the United States published a paper titled "Functional amyloid proteins confer defence against predatory bacteria" in Nature. In this study, the authors found that functional amyloid proteins are not only pathologically related structures but also a class of widely present and highly adaptive defense barriers. They form extracellular fibrillar networks, protecting host bacteria from predators and viruses.[1]Ledvina, H.E., Sayegh, R., Carale, R.O. et al. Functional amyloid proteins confer defence against predatory bacteria. Nature (2025). https://doi.org/10.1038/s41586-025-09204-7
'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)